Shares of ImmunityBio (IBRX) experienced a massive rally, surging 41.36% to reach $8.51 following significant regulatory news from Europe. The European Commission has granted conditional marketing authorization for the company's immunotherapy drug, ANKTIVA, specifically for the treatment of bladder cancer. This approval represents a major milestone, significantly expanding the company's commercial reach within the global oncology market. Following the stock's jump, ImmunityBio's market capitalization has risen to approximately $5.9 billion, reflecting strong investor confidence. Regulatory milestones are primary catalysts for biotech stocks, often leading to substantial shifts in valuation and revenue potential. The expansion into the European market is expected to bolster the company's long-term market position and growth trajectory.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis